About eGenesis
eGenesis is a Healthcare company based in Cambridge (United States) founded in 2015 by George M Church. Gene transplantation platform for humanizing pig cells is developed. eGenesis has raised $495.42 million across 8 funding rounds from investors including Bayer, ARE and DaVita. The company has 94 employees. eGenesis has completed 1 acquisition, including ICBiotec. Its chief executive, as recorded, is Michael Curtis. eGenesis offers products and services including EGEN Platform and HuCo Organs. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Technology Platforms. Its legal entity is EGENESIS, INC. Its competitors include Beam Therapeutics, Korro Bio and Metagenomi; 3 of its 3 listed competitors have raised funding.
Company details
eGenesis was founded in 2015 and is based in Cambridge, United States. Operations focus on the biotechnology sector, where a gene transplantation platform is utilized to humanize pig cells for producing human-compatible organs. This technology relies on next-generation genome engineering and CRISPR tools. Organs grown in donor pigs are harvested for safe transplantation into human patients, addressing needs in organ transplantation.
- Headquarters Cambridge, United States
- Employees 94
- Founders George M Church
- SectorsHealthcare
- Email••••••••
- Website egenesisbio.com
- Social LinkedIn X Facebook
- Legal Name Egenesis, Inc.
Products & Services of eGenesis
eGenesis offers a comprehensive portfolio of products and services, including EGEN Platform and HuCo Organs.
Tool for engineering organs to overcome xenotransplantation barriers.
Genetically modified porcine organs for human compatibility.
Funding Insights of eGenesis
eGenesis has successfully raised a total of $495.42M across 8 strategic funding rounds. The most recent funding activity was a Series D round of $14 million completed in August 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $495.42M
- Total Rounds 8
- Last Round Series D — $14M
- First Round $2M
(Aug 2016)
- Investors Count 28
All 8 funding rounds of eGenesis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2026 | $14M | Series D | – | – | |
| Sep 2024 | $191M | Series D | – | Lux Capital | |
| Feb 2024 | $25.42M | Series C | – | – | – |
| Jan 2024 | Series C | – | – | ||
| Mar 2021 | $125M | Series C | – | Farallon Capital Management, Polaris Partners | |
| Nov 2019 | $100M | Series B | – | Fresenius Medical Care | |
| Mar 2017 | $38M | Series A | – | Biomatics Capital, Arch Venture Partners | |
| Aug 2016 | $2M | Seed | – | – | – |
28 investors in total: 28 institutional.
Investors in eGenesis
eGenesis has secured backing from 28 investors, including institutional and venture fund investors. Prominent investors backing the company include Bayer, ARE and DaVita.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Seed and early-stage technology companies are funded by Lux Capital. | luxcapital.com | Menlo Park, United States | ||
Venture capital firm focused on life science companies | 1986 | archventure.com | Chicago, United States | |
Early-stage startups are funded by this venture capital firm. | 2004 | khoslaventures.com | Menlo Park, United States | |
Multiple investment strategies are pursued by this hedge fund. | 1986 | faralloncapital.com | San Francisco, United States | |
Venture capital firm focused on healthcare companies | altapartners.com | Jackson, United States | ||
Venture capital firm investing in life sciences sector | leaps.bayer.com | Leverkusen, Germany | ||
Private equity firm focused on biotech and healthcare sectors | eisaiinnovation.com | Cambridge, United States | ||
US focused venture capital firm | polarispartners.com | Boston, United States | ||
Long-term private equity investments in transformational opportunities are pursued. | invus.com | New York, United States | ||
Life sciences focused VC firm funding companies in the US and Europe | 2001 | hbmhealthcare.com | Zug, Switzerland |
Investor details for eGenesis
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of eGenesis
54 people are tracked at eGenesis (23 in leadership, 9 in board & advisors, 22 in team); the tracked headcount is 94.
| Name | Role | Group |
|---|---|---|
George M Church | Co-Founder | Leadership |
Michael Curtis | CEO & President | Leadership |
Susan Low | Head, Development | Leadership |
Bjoern Petersen | Vice President Of Manufacturing | Leadership |
Mike Curtis | President & CEO | Leadership |
Elizabeth Roberts | Chief People Officer | Leadership |
Amanda Marett | Associate Director Of Production And Project Allocation | Leadership |
Sagar Chhangawala | Director, Computational Biology | Leadership |
Lee W. Tien | Sr. Director, Business Development And Alliance Management | Leadership |
Annie Delgaudio | Business Partner, Learning And Development Lead | Leadership |
Caroline McNicoll | People Operations Business Partner & Talent Acquisition Lead | Leadership |
Rebecca Knott | Director, People Operations | Leadership |
Wes Westlin | Executive Vice President, Research & Develop | Leadership |
Sarah S. | Associate Director - Clinical Development | Leadership |
Kashif Sheikh | Director, QA | Leadership |
Jennifer Bergheiser | Chief Business Officer | Leadership |
Ahmad Zaidan | Director, Information Technology & Cyber Security | Leadership |
Matthew Williams | Associate Director, Quality Systems And Compliance | Leadership |
Krunal Soni | Sr. Director, Head Of Quality | Leadership |
Lauren Tahmoush | Vice President, Finance | Leadership |
34 more people are available in the full profile.
Complete people profiles for eGenesis
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by eGenesis
eGenesis has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include ICBiotec.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Provider of gene editing platform for the development of human-compatible organs, tissues and cells | icbiotec.com | Mount Horeb, United States | 1998 | May 2020 | •••• |
Complete acquisition details for eGenesis
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of eGenesis
4 dated milestones of eGenesis across 11 years, from founding to its latest funding, stage changes and deals.
- Founded eGenesis is founded.
- Funding First funding round of $2.0M.
- Acquisition Acquires ICBiotec.
- Funding Latest funding round, Series D, of $14.0M.
Competitors of eGenesis
eGenesis has 3 listed competitors in our database, 3 of them funded. They include Beam Therapeutics, Korro Bio and Metagenomi.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| beamtx.com | 2017 | Cambridge, United States | $222M | 340 | Developer of gene therapy using CRISPR base editing to treat diseases | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. | |
| metagenomi.co | 2016 | Berkeley, United States | $376.37M | Next-generation gene editing tools are developed for drug enhancement. |
Detailed competitors of eGenesis
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of eGenesis
The website of eGenesis (egenesisbio.com) receives about 4.7K visits a month.
- Monthly visits4.7K
▼ 2.5% vs previous month
Websites whose visitors overlap most with eGenesis. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| wyss.harvard.edu | 77% | 124.2K | View details |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as eGenesis (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Egenesis
Complete news archive for eGenesis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about eGenesis
eGenesis was founded in 2015 and raised its 1st funding round 1 year after it was founded.
eGenesis is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Michael Curtis is the CEO of eGenesis, as recorded in our data.
eGenesis is a funded company, having raised a total of $495.42M across 8 funding rounds to date. The company's 1st funding round was a Seed of $2M, raised on Aug 2016.
eGenesis has 94 employees.
eGenesis was founded in 2015 and is based in Cambridge, United States. Operations focus on the biotechnology sector, where a gene transplantation platform is utilized to humanize pig cells for producing human-compatible organs. This technology relies on next-generation genome engineering and CRISPR tools. Organs grown in donor pigs are harvested for safe transplantation into human patients, addressing needs in organ transplantation.
eGenesis's top competitors include Korro Bio, Beam Therapeutics and Metagenomi.
eGenesis offers EGEN Platform and HuCo Organs.
eGenesis has made 1 acquisition, including ICBiotec.
eGenesis has 28 investors. Key investors include Bayer, ARE, DaVita, Natco Pharma, and Khosla Ventures.
eGenesis operates through Egenesis, Inc..